Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JNJ-69968054 by Johnson & Johnson for Escherichia coli Infections: Likelihood of Approval
JNJ-69968054 is under clinical development by Johnson & Johnson and currently in Phase III for Escherichia coli Infections. According to...